News
For a while, Danish drugmaker Novo Nordisk A/S looked unstoppable. It was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat ...
Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...
U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
2don MSN
Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...
Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results